BPI-1178
Phase 2Small molecule
BPI-1178 is one of 75 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
BPI-1178
BBeta Pharma (Suzhou) Co., Ltd.
Phase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPI-1178. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeta Pharma (Suzhou) Co., Ltd.